Join us for the 8th Annual March for Marrow 5K Run & Walk and help us find a cure for
Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant
Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
On September 1, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML).
The approval covers the use of gemtuzumab in adults with newly diagnosed AML that expresses a protein called CD33 (CD33-positive AML). The approval also covers the treatment of patients aged 2 and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.
A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment.
Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.
Thank you for attending the 2017 Minneapolis Patient and Family Conference.
Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ~12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, leading to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.